Evaluation of Humoral Immunogenicity in Diabetes Patients Six Months Post-Second Dose: Comparative Analysis of BNT162b2, ChAdOx1 nCoV-19, and BBIBP-CorV Vaccines
DOI:
https://doi.org/10.46966/msjar.v5i1.169Keywords:
Covid-19 vaccine, Diabetes, SARS-COV2, Neutralization antibody, Humoral response.Abstract
Background: Diabetes mellitus patients are usually considered a high risk population for SARS –COV2 infection and shown blunted immune responses when vaccinated with different types of vaccines. Aims: The study aimed to compare the humoral immune response at one to six months post the second dose of BNT162b2, ChAdOx1 nCoV-19, and BBIBP-CorV vaccine in diabetes people. The humoral immune response was assessed by determining SARS-CoV-2 Spike IgG antibodies, and SARS-CoV-2 Neutralization Antibody inhibition %. Materials and methods: A total of 180 participants with diabetes were eligible for analysis. chemiluminescent immunoassay (CLI) quantify SARS-COV-2 spike protein IgG antibody and Enzyme linked immunoassay (ELISA) was used to SARS-CoV-2 Neutralization Antibody inhibition % at most during the six months after the second dose of vaccination. Results: BNT162b2 vaccine induce a highest levels of anti-S IgG antibody and NAB IH5% (25.66±1.67 AU\mL, 76.32±11.6% respectively), followed by ChAdOx1 nCoV-19 (11.53±2.11 AU\Ml, 69.62±14.53 % respectively) and BBIBP-CorV (51.32±11.6 AU\Ml, 7.84±2.41 % respectively) (p<0.001) after six months post second dose of vaccination. The impaired antibodies response by BBIBP-CorV vaccine suggests that the vaccine may be less effective in generating a robust immune response in diabetes patients. Furthermore, Sex, Age, and duration were significantly correlated with levels of antibodies. Conclusions: The long-term humoral immunogenicity of several COVID-19 vaccinations in individuals with diabetes is clarified by this study. After six months, BNT162b2 exhibited better humoral immune responses followed by ChAdOx1nCoV-19 and BBIBP-CorV vaccines. Sex, age, and duration after vaccination were correlated with IgG antibody levels and NAB-IH%. These results emphasize the significance of taking into account the type of vaccine and the patients' long-term immune responses when developing an effective COVID-19 immunization strategy.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Dhuhah Hayder Abdul-Jawad, Ameer Mezher Hadi, Zahraa Basem Shaker, Hussein Bahaa Abd. Alrzaaq4, Musa Nima Mezher, Estabraq Hassan Badder Al-Muhanna
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
